Table 7.
Obesity-related comorbidities at 6 months postoperatively, n (%)
|
|
n
|
1SO, n = 73 | 1FAO, n = 73 |
χ
2
|
P value
|
n | 2SO, n = 53 | 2FAO, n = 53 |
χ
2
|
P value
|
|
| MS | Without | 133 | 65 (89) | 68 (93.2) | 0.760 | 0.383 | 100 | 52 (98.1) | 48 (90.6) | 0.205 | |
| With | 13 | 8 (11.0) | 5 (6.8) | 6 | 1 (1.9) | 5 (9.4) | |||||
| HTN | Without | 132 | 66 (90.4) | 66 (90.4) | > 0.999 | 99 | 50 (94.3) | 49 (92.5) | > 0.999 | ||
| With | 14 | 7 (9.6) | 7 (9.6) | 7 | 3 (5.7) | 4 (7.5) | |||||
| T2DM | Without | 131 | 66 (90.4) | 65 (89.0) | 0.074 | 0.785 | 97 | 52 (98.1) | 45 (84.9) | 0.031 | |
| With | 15 | 7 (9.6) | 8 (11.0) | 9 | 1 (1.9) | 8 (15.1) | |||||
| HLP | Without | 118 | 60 (82.2) | 58 (79.5) | 0.177 | 0.674 | 91 | 50 (94.3) | 41 (77.4) | 6.290 | 0.012 |
| With | 28 | 13 (17.8) | 15 (20.5) | 15 | 3 (5.7) | 12 (22.6) | |||||
| NAFLD | Without | 96 | 55 (75.3) | 41 (56.2) | 5.962 | 0.015 | 65 | 40 (75.5) | 25 (47.2) | 8.949 | 0.003 |
| With | 50 | 18 (24.7) | 32 (43.8) | 41 | 13 (24.5) | 28 (52.8) | |||||
| HUA | Without | 98 | 46 (63.0) | 52 (71.2) | > 0.999 | 78 | 41 (77.4) | 37 (69.8) | 1.603 | 0.205 | |
| With | 48 | 27 (37.0) | 21 (28.8) | 28 | 12 (22.6) | 16 (30.2) | |||||
Significant postoperative remission of obesity-related comorbidities in all patient groups (P < 0.001). SO: Sporadic obesity; FAO: Familial aggregation of obesity; MS: Metabolic syndrome; HTN: Hypertension; T2DM: Type 2 diabetes mellitus; HLP: Hyperlipoidemia; NAFLD: Non-alcoholic fatty liver disease; HUA: Hyperuricemia.